Dartmouth-Hitchcock logo
Back
 
Opioid Use for Headache Treatment

This module is an overview of opioid effects on the nervous system and their consequences in drug-opposite effects and discusses the controlled therapeutic trials of opioids for headache treatment. Participants will discover and be able to trace the downstream adverse clinical consequences of opioid use in brain, in headache patients, and in opioid use for control of pain.

Activity Details
Start Date: December 22, 2017
End Date: December 22, 2019

You may claim CME credit for successful completion of this online course. In order to claim credit, you must follow these steps:

  1. Register for the learning activity by creating an account or logging in to your account.
  2. Click Continue to navigate to the Activity Material tab. Click View Presentation to view the recording.
  3. Return to this Activity page.
  4. Click Continue to navigate to the Evaluation tab; then click the Launch button to start the evaluation.
  5. Complete and Submit the evaluation and attestation form.

When the evaluation is submitted, you will be awarded credit. You may access your transcript for verification of participation at any time via Your Account. Need help? Visit the Support Page, send an Email, or call the Center for Learning and Professional Development at (603) 653-1234, Option 1.

Presenter
  • Stewart Tepper, MD
    Professor of Neurology
    Dartmouth-Hitchcock
Learning Outcome(s)

Participants will be able to discuss controlled therapeutic trials of opioids for headache and opioid effects on the nervous system and their consequences in drug-opposite effects. They will be able to describe adverse clinical consequences of opioid use in brain, in headache patients, and the use in control of pain.

Accreditation

Dartmouth-Hitchcock is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Dartmouth-Hitchcock designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Requirements for Successful Completion

In order to receive credit for this Continuing Medical Education (CME) activity, you must:

  • View the entire presentation
  • Complete the activity evaluation. (you must register to access).
Speaker Disclosure

In accordance with the disclosure policy of Dartmouth-Hitchcock/Geisel School of Medicine at Dartmouth as well as standards set forth by the Accreditation Council on Continuing Medical Education and the Nursing Continuing Education Council standards set forth by the American Nurses Credentialing Center Commission on Accreditation, continuing medical education and nursing education activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have been asked to disclose any financial relationship* they have to a commercial interest (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients). Such disclosure is not intended to suggest or condone bias in any presentation, but is elicited to provide participants with information that might be of potential importance to their evaluation of a given activity.

The Physician Director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for Opioid Use for Headache Treatment (Neurology Grand Rounds) have reported the following financial interest or relationship* with various companies/organizations. The Speaker role was resolved by validating the activity content through independent peer review by the Activity Director, Nathaniel Robbins, MD. All potential conflict(s) were resolved.

  • Stewart Tepper, MD ~ has research/grant support (no personal compensation) from Alder, Allergan, Amgen, ATI, Avanir, Dr. Reddy’s Electrocare, eNeura, Scion, Teva and Zosano. Dr. Tepper is a consultant to Acorda, Alder, Allergan, Amgen, ATI, Avanir, Dr. Reddy’s Electrocore, eNeura, Eli Lilly, GLG, Guidepoint Global, Kimberly Clark, Novartis, Pernix, Pfizer, Scion, Slingshot Insights, Supernus, Teva, and Zosano. Dr. Tepper has stock options from ATI and has salary support from The American Headache Society for editorship.

Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this program report no financial interest or relationship* with any company(ies) or organizations whose product may be germane to the content of their presentations.

*A “financial interest or relationship" refers to an equity position, receipt of royalties, consultantship, funding by a research grant, receiving honoraria for educational services elsewhere, or to any other relationship to a company that provides sufficient reason for disclosure, in keeping with the spirit of the stated policy.

Provider Contact Information

Provider contact information for questions regarding accreditation of the activity:
Center for Learning and Professional Development
Dartmouth-Hitchcock Medical Center
clpd.support@hitchcock.org

For more information on this topic, please go to: https://www.oplc.nh.gov/medicine/opioid-prescribing.htm


Type:     Internet Activity (Enduring Material)
128 Registered Users

0